Treatment Options for Chronic GVHD (cGVHD): Evaluating Axatilimab (Anti-CSF-1R Antibody) Potential in Third Line or Greater

Corey Cutler, MD, MPH, and Hannah Choe, MD, provide an overview of chronic graft-vs-host disease (GVHD) and identify characteristics that differentiate it from acute GVHD.

Hematologic oncologists review therapeutic options for patients with chronic GVHD and provide clinical insights on their treatment approaches.

Corey Cutler, MD, MPH, discusses how axatilimab’s mechanism of action differs from currently available therapies for patients with chronic GVHD.

Hannah Choe, MD, provides insights on potential areas for improvement in developing more targeted and effective treatments for chronic GVHD.

A hematologist provides an overview of the AGAVE-201 trial investigating axatilimab in patients with chronic graft-vs-host disease.

Experts on graft-vs-host disease discuss the potential role for axatilimab within current treatment algorithms.

Corey Cutler, MD, MPH, and Hannah Choe, MD, provide future perspectives on the development of axatilimab for patients with chronic GVHD.